Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
Combined vaccine formulations targeting not only hemagglutinin but also other influenza virus antigens could form the basis for a universal influenza virus vaccine that has the potential to elicit long-lasting, broadly cross-reactive immune responses.
ESWI Summit 2022: Expert panel view – Aeron Hurt
ESWI Summit 2022 – Stakeholder Debate
COVID-19 Treatment and Medication
Third webinar in the series: Preparing for COVID-19, RSV disease and Inlfuenza concomitant outbreaks, chaired by Ab Osterhaus and Marco G...